Actively Recruiting
Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels
Led by dsm-firmenich Switzerland AG · Updated on 2026-04-23
200
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
Sponsors
D
dsm-firmenich Switzerland AG
Lead Sponsor
B
BioFortis
Collaborating Sponsor
AI-Summary
What this Trial Is About
The placebo-controlled, double blind parallel intervention trial "PostWelLB" aims to test whether 3 months of daily supplementation with the postbiotic product "Humiome® Post LB" (HPLB; 340 mg / day) can reduce self-reported stress (PSS10 questionnaire)- in an older (50 - 75 years; all genders) population in France.
CONDITIONS
Official Title
Effect of Daily Humiome® Post LB Intake on Wellbeing in Older Individuals With Moderate Stress Levels
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women aged between 50 and 75 years old (limits included)
- Body mass index (BMI) 8 18.5 and < 30 kg/m2
- Presenting a level of psychological stress characterized by a PSS-10 score 8 14 and 8 26
- For women: not at risk of pregnancy and using effective contraception if of childbearing potential
- Menopausal women without hormone replacement therapy or stopped estrogenic replacement therapy more than 3 months ago
- Good general and mental health with no relevant medical abnormalities
- Agree to maintain current lifestyle habits during the study
- Able and willing to comply with study procedures and sign informed consent
- Affiliated with a social security scheme
- Have access to a healthcare provider and emergency health services
- Agree to be registered in the national clinical research database
- Have a smartphone or personal computer compatible with study applications
You will not qualify if you...
- Suffering from metabolic disorders such as diabetes or thyroid dysfunction treated less than 6 months ago or unstable
- Having severe chronic diseases including cancer, HIV, renal failure, liver or biliary disorders (except cholecystectomy over 2 years ago), chronic inflammatory digestive disease, arthritis, or chronic respiratory troubles except mild asthma under treatment
- Having gastrointestinal disorders inconsistent with study conduct (e.g., celiac disease, Crohn's disease)
- Known food allergies or intolerances to any study product ingredients
- Pregnant, lactating, or planning pregnancy within six months
- History or presence of psychiatric or neurologic diseases that could affect study results
- Recent or current significant stress events as judged by investigator
- Conditions or treatments causing immunosuppression
- Recent use (less than one month) of treatments or supplements affecting study parameters, including psychotropic, stimulant, narcotic, sleep aid medications, antihistamines, acid-blocking medications, or antibiotics
- Lifestyle incompatible with study, such as high physical activity over 10 hours per week, excessive alcohol consumption, or recent significant diet or activity changes
- Personal history of significant eating disorders
- Participation in another clinical trial or within exclusion period
- Received clinical trial compensations equal or above 6000 Euros in last 12 months
- Under legal protection or deprived of rights
- Psychological or linguistic incapacity to consent or unreachable in emergencies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Biofortis
Saint-Herblain, France, 44800
Actively Recruiting
Research Team
E
Eleonora Rossi, PhD
CONTACT
E
Erik Eckhardt, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here